A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Inclusion Criteria: * Histologically confirmed intracranial Grade 3 or 4 anaplastic glioma or glioblastoma (astrocytic tumor, anaplastic oligodendroglioma, or oligoastrocytoma) * Received prior standard radiation for a Grade 3 or 4 astrocytic tumor with a minimum cumulative dose of 40 Gy administered * Completed at least one full cycle of temozolomide of 200 mg/m2/day administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression * Karnofsky performance status of 60 or more * Adequate organ and bone marrow function as defined by hematological and serum chemistry limits * At least 18 years old. * Both men and women must practice adequate contraception * Informed consent Exclusion Criteria: * Progressed while on temozolomide * Evidence of acute intracranial or intratumoral hemorrhage \> Grade 1 * Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including cytotoxic chemotherapy other than temozolomide, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents, prior therapy with a PI3K inhibitors, radiation therapy, enzyme-inducing anti-convulsants, valproic acid * Not recovered from the toxic effects of prior therapy * Pregnant or breast feeding * History of diabetes mellitus * Uncontrolled intercurrent illness * Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study. * HIV positive * Diagnosis of another malignancy may exclude subject from study